Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 5Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Neoplasms 2Carcinoma, Ovarian Epithelial 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Multiple Myeloma 1Melanoma 1Lung Cancer - Malignant Pleural Mesothelioma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Hemangiosarcoma 1Esophagogastric Cancer 1Esophageal Neoplasms 1Disorders of Sex Development 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

enzalutamide 2pazopanib 1capivasertib 1Watchful Waiting 1STA 9090 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiosurgery 1Dutasteride 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma of the Prostate × STA 9090 × Clear all
NCT01368003 2015-09-01

STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Genitourinary

Adenocarcinoma of the Prostate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡